Vésale Bioscience is at the forefront of developing precision phage therapy as a solution to combat antimicrobial resistance (AMR), a growing public health crisis. The company focuses on harnessing bacteriophages—viruses that specifically target and kill bacteria—to create personalized and effective treatments for infections caused by multi-resistant bacteria. Their innovative approach aims to provide selective and specific therapies that can adapt to the unique bacterial profiles of individual patients, thereby addressing the urgent need for alternatives to traditional antibiotics.

In addition to their medical applications, Vésale Bioscience is exploring the use of phage therapy in veterinary medicine, particularly as a sustainable alternative to combat antibiotic resistance in animal production. The company has received significant recognition for its efforts, including a €1.8 million grant from the European Innovation Council to support the development of its diagnostic tools that facilitate personalized phage therapies. This commitment to research and development positions Vésale Bioscience as a leader in the fight against superbugs and highlights the potential of phage therapy as a transformative solution in both human and veterinary healthcare.

Belgium

Stem from our advanced R&D on bacteriophages, our Mission is to develop robust modern solutions to fight drug-resistant infections.

Antimicrobial resistance (AMR) is a substantial public health issue. From 700 000/y deaths today, the AMR burden is expected to reach ten million/y deaths by 2050, more than cancer.

Our approach is to work on personalized, selective, and specific phage therapies against those multi-resistant bacterial infections.


Vésale Bioscience

Company Details